Text Size
330 studies found for:    "Myelofibrosis"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Intervention: Drug: imetelstat sodium
22 Active, not recruiting Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: cyclophosphamide;   Drug: busulfan;   Drug: tacrolimus;   Drug: methotrexate;   Genetic: cytogenetic analysis;   Other: flow cytometry;   Other: pharmacological study;   Other: pharmacogenomic studies;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
23 Active, not recruiting Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Conditions: Primary Myelofibrosis (PMF);   Post-Polycythaemia Vera;   Essential Thrombocythaemia Myelofibrosis
Intervention: Drug: AZD1480
24 Recruiting A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INC424;   Drug: BKM120
25 Active, not recruiting
Has Results 		COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
26 Active, not recruiting
Has Results 		Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Condition: Myelofibrosis
Interventions: Drug: INC424/INCB018424;   Drug: Best Available Therapy (BAT)
27 Completed Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
Conditions: Chronic Myeloproliferative Disorders;   Secondary Myelofibrosis
Interventions: Drug: cyclophosphamide;   Drug: prednisone;   Drug: thalidomide;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
28 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
29 Recruiting Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Condition: Myelofibrosis
Intervention: Drug: SAR302503
30 Completed Study of INCB018424 Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: INCB018424 (ruxolitinib)
31 Completed Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: APLIDIN (plitidepsin)
32 Terminated
Has Results 		Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Conditions: Chronic Myeloproliferative Disorders;   Secondary Myelofibrosis
Intervention: Drug: Dacogen
33 Completed Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocytopenia
Intervention: Drug: Panobinostat
34 Active, not recruiting Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence
Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide;   Other: Placebo
35 Recruiting Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Condition: Myelofibrosis
Interventions: Drug: Panobinostat;   Drug: Ruxolitinib
36 Active, not recruiting
Has Results 		Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Thrombocytosis
Intervention: Drug: Ruxolitinib
37 Completed
Has Results 		CEP-701 for PH-negative Myelofibrosis
Conditions: Leukemia;   Myelofibrosis
Intervention: Drug: CEP-701
38 Completed Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
39 Active, not recruiting Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Thymoglobulin (ATG)
40 Completed A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: TG101348
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years